Posts Tagged ‘leukemia’

jon frampton

June 19th, 2010

The application of our rapidly expanding knowledge about stem cells will revolutionise the future of medicine, says Jon Frampton, Professor of Stem Cell Biology and Director of the Stem Cell Centre at the University of Birmingham.

His Centre covers a wide range of research areas from neural stem cells, skeletal muscle stem cells, tooth stem cells and germ cells derived from embryonic stem cells to studies on 3D materials for tissue engineering.  Complementing these research efforts, the Centre also includes a number of members of the School of Social Sciences who help to provide a broad perspective on social and ethical issues associated with stem cell research.

Of his own major research interests, Professor Frampton focuses on the regulation of stem cell behaviour in health and disease.  In particular, I am interested in blood stem cells, both normal and those related to leukaemia, although other studies encompass a number of adult stem cell types, for example, those giving rise to bone and fat and the resident stem cells in the heart.

Before coming to Birmingham, he ran research groups in the European Molecular Biology Laboratory in Heidelberg (1988-1995) and the Weatherall Institute of Molecular Medicine at the University of Oxford (1995-2002).

charles craddock

June 10th, 2010

Some kinds of leukemia and myeloma have been traditionally very difficult to treat, and put patients through punishing chemotherapy which only sometimes worked. This situation has recently changed dramatically.

Charles Craddock Director of the Blood and Marrow Transplant Unit at University Hospital Birmingham NHS Foundation Trust says there are now exciting novel transplant and drug therapies, transforming patients’ lives, enabling many to live longer and fuller lives than was ever thought possible only a few years ago.

Charles Craddock is Professor of Haematolo-oncology at the University of Birmingham as well as Director of the Blood and Marrow Transplant Unit at University Hospital Birmingham NHS Foundation Trust. He has a particular research interest in the development of novel transplant and drug therapies in leukemia and myeloma. He also works with groups researching chromatin structure in acute-myeloid leukemia, mechanisms of drug resistance in myeloma and characterisaation of dysregulated signalling pathways in leukemia using proteomics.